Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Hyperlipidemia: therapeutic principles in clinical practice].

Dirk Müller-Wieland1, Wilhelm Krone

  • 1Abteilung für Klinische Biochemie und Pathobiochemie, Deutsches Diabetes-Forschungsinstitut, Heinrich-Heine-Universität, Düsseldorf. mueller-wieland@ddfi.uni-duesseldorf.de

Medizinische Klinik (Munich, Germany : 1983)
|December 20, 2003
PubMed
Summary

Assessing individual cardiovascular risk is crucial for managing coronary heart disease. Recommended low-density lipoprotein (LDL) cholesterol targets vary based on 10-year risk, guiding therapeutic interventions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discovering heart failure patient pathways through event enrichment and abstraction.

International journal of medical informatics·2026
Same author

Very strong correlations of metoprolol- and solanidine-derived metabolic ratios in a real-world cohort with a stable metoprolol drug regimen.

Frontiers in pharmacology·2026
Same author

Lipoprotein(a) and residual cardiovascular risk in statin-treated patients.

European journal of preventive cardiology·2026
Same author

Diabetes Mellitus and the Heart.

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association·2026
Same author

Prediction or speculation: heart failure models for diabetes.

European journal of heart failure·2026
Same author

CVOT Summit Report 2025: advances along the cardiovascular-kidney-metabolic disease continuum.

Cardiovascular diabetology·2026

Area of Science:

  • Cardiology
  • Pharmacology
  • Biochemistry

Context:

  • Coronary heart disease prognosis depends on plaque vulnerability, not just stenosis.
  • Individual cardiovascular risk assessment is essential for setting therapeutic LDL cholesterol goals.
  • European guidelines now consider total cardiovascular mortality risk.

Purpose:

  • To outline LDL cholesterol targets based on coronary and total cardiovascular risk.
  • To review non-pharmacologic and pharmacologic interventions for lowering LDL cholesterol.
  • To highlight ezetimibe's novel mechanism in cholesterol absorption inhibition.

Summary:

  • Recommended LDL cholesterol levels are <100 mg/dl for >20% risk, <130 mg/dl for 10-20% risk, and <160 mg/dl for <10% risk.
  • Interventions include lifestyle changes and various drug classes, such as statins and ezetimibe.

Related Experiment Videos

  • Ezetimibe selectively inhibits intestinal absorption of cholesterol and phytosterols, offering a new therapeutic approach.

    • Impact:

    • Provides a framework for personalized LDL cholesterol management in cardiovascular disease.
    • Introduces ezetimibe as a valuable agent, particularly in combination therapy and for specific hypercholesterolemic conditions.
    • Emphasizes the importance of considering total cardiovascular risk for effective patient care.